These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 10889595)

  • 1. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period.
    Ling AE; Robbins KE; Brown TM; Dunmire V; Thoe SY; Wong SY; Leo YS; Teo D; Gallarda J; Phelps B; Chamberland ME; Busch MP; Folks TM; Kalish ML
    JAMA; 2000 Jul; 284(2):210-4. PubMed ID: 10889595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First report of human immunodeficiency virus transmission via an RNA-screened blood donation.
    Delwart EL; Kalmin ND; Jones TS; Ladd DJ; Foley B; Tobler LH; Tsui RC; Busch MP
    Vox Sang; 2004 Apr; 86(3):171-7. PubMed ID: 15078251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.
    Schmidt M; Korn K; Nübling CM; Chudy M; Kress J; Horst HA; Geusendam G; Hennig H; Sireis W; Rabenau HF; Doerr HW; Berger A; Hourfar MK; Gubbe K; Karl A; Fickenscher H; Tischer BK; Babiel R; Seifried E; Gürtler L
    Transfusion; 2009 Sep; 49(9):1836-44. PubMed ID: 19453990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor.
    Phelps R; Robbins K; Liberti T; Machuca A; Leparc G; Chamberland M; Kalish M; Hewlett I; Folks T; Lee LM; McKenna M
    Transfusion; 2004 Jun; 44(6):929-33. PubMed ID: 15157262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations.
    Najioullah F; Barlet V; Renaudier P; Guitton C; Crova P; Guérin JC; Peyramond D; Trabaud MA; Coudurier N; Tardy JC; André P
    J Med Virol; 2004 Jul; 73(3):347-9. PubMed ID: 15170627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.
    Weusten JJ; van Drimmelen HA; Lelie PN
    Transfusion; 2002 May; 42(5):537-48. PubMed ID: 12084161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 NAT minipool during the pre-seroconversion window period: detection of a repeat blood donor.
    Palla P; Vatteroni ML; Vacri L; Maggi F; Baicchi U
    Vox Sang; 2006 Jan; 90(1):59-62. PubMed ID: 16359357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets.
    Chudy M; Weber-Schehl M; Pichl L; Jork C; Kress J; Heiden M; Funk MB; Nübling CM
    Transfusion; 2012 Feb; 52(2):431-9. PubMed ID: 21810100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe.
    Roth WK; Weber M; Buhr S; Drosten C; Weichert W; Sireis W; Hedges D; Seifried E
    Transfusion; 2002 Jul; 42(7):862-8. PubMed ID: 12375658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing.
    Cappy P; Barlet V; Lucas Q; Tinard X; Pillonel J; Gross S; Tiberghien P; Laperche S
    Transfusion; 2019 Jun; 59(6):2046-2053. PubMed ID: 30784073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of an early HIV-1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period.
    Aprili G; Gandini G; Piccoli P; Bressan F; De Gironcoli M; Mazzi R; Parisi SG; Gessoni G; Marchiori G; Franchini M
    Transfusion; 2003 Jul; 43(7):848-52. PubMed ID: 12823742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios.
    Bruhn R; Lelie N; Custer B; Busch M; Kleinman S;
    Transfusion; 2013 Oct; 53(10 Pt 2):2399-412. PubMed ID: 23782054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk.
    Vermeulen M; Coleman C; Mitchel J; Reddy R; van Drimmelen H; Fickett T; Busch M; Lelie N
    Transfusion; 2013 Oct; 53(10 Pt 2):2384-98. PubMed ID: 23445273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing.
    Müller B; Nübling CM; Kress J; Roth WK; De Zolt S; Pichl L
    Transfusion; 2013 Oct; 53(10 Pt 2):2422-30. PubMed ID: 23782012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.
    Hyland C; Seed CR; Kiely P; Parker S; Cowley N; Bolton W
    Vox Sang; 2003 Jul; 85(1):1-8. PubMed ID: 12823724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV transmissions from a window-period platelet donation.
    Kopko PM; Fernando LP; Bonney EN; Freeman JL; Holland PV
    Am J Clin Pathol; 2001 Oct; 116(4):562-6. PubMed ID: 11601141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.
    Busch MP; Glynn SA; Stramer SL; Strong DM; Caglioti S; Wright DJ; Pappalardo B; Kleinman SH;
    Transfusion; 2005 Feb; 45(2):254-64. PubMed ID: 15660836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus 1 dual-target nucleic acid technology improves blood safety: 5 years of experience of the German Red Cross blood donor service Baden-Württemberg-Hessen.
    Hourfar K; Eberle J; Müller M; Micha Nübling C; Chudy M; Kress J; Gürtler L; Mayr-Wohlfart U; Schrezenmeier H; Hellmann I; Luhm J; Kraas S; Ringwald J; Gubbe K; Frank K; Karl A; Tonn T; Jaeger M; Sireis W; Seifried E; Schmidt M
    Transfusion; 2018 Dec; 58(12):2886-2893. PubMed ID: 30325043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.